JAK2 and essential thrombocythemia: In 2005, somatic mutation in JAK2 exon 14 (JAK2 V617F) was first reported to occur in over 95% of PV and approximately 50% of ET and PMF patients, resulting in the auto-activation of this tyrosine kinase and enhanced signaling of the down-stream JAK-STAT pathway [[5],[6]].